Drug combo plus radiation for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new combination of two drugs (fruquintinib and sintilimab) plus focused radiation for people with advanced stomach or gastroesophageal junction cancer that has progressed after earlier treatments. The goal is to see if this approach can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have stomach or gastroesophageal junction cancer that has spread or is locally advanced, and it must have worsened after at least one prior treatment.
- You must have at least one tumor that can be measured by scans.
- You must be generally active and able to care for yourself (ECOG score 0-1).
- Your organs must be functioning well enough, based on blood tests and heart tests.
- You must not have had certain previous treatments or conditions listed in the trial rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs—fruquintinib, sintilimab, and XELOX chemo—for advanced stomach cancer. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests a combination of three drugs — a chemotherapy called irinotecan liposome, a targeted therapy called fruquintinib, and an immunotherapy called sintilimab — for people with advanced stomach cancer whose disease has worsened after their first treatment. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and FOLFOX chemotherapy) as the first treatment for advanced gastric (stomach) cancer. The goal is to see if this combination is safe and effective in shrinking tumors or slowing the cancer's growth.
This trial tests a combination of two drugs (fruquintinib and albumin-paclitaxel) with or without an immunotherapy drug (PD-1 antibody) as a second-line treatment for advanced stomach cancer. It aims to see if adding immunotherapy improves outcomes for people who have already received immunotherapy before.
This trial tests a combination of two drugs, fruquintinib and TAS102, for people with advanced stomach cancer that has stopped responding to at least one prior chemotherapy. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs (fruquintinib, sintilimab, and CAPEOX chemotherapy) as a first treatment for advanced stomach or gastroesophageal cancer. The goal is to see if this combination helps slow or shrink the tumor.
Hear when a new Gastric Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.